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Introduction 
Photodynamic Therapy (PDT) is a treatment that uses a drug, called photosensitizer, and a light 
of specific wavelength to treat certain diseases. [2] Each photosensitizer is activated by a specific 
wavelength of light, which determines how far the light can penetrate into the body. PDT, 
involves the cell destruction due to the singlet oxygen (102) and/or other free radicals which are 
generated from a sequence of photochemical and photo biological reactions.[1] 
 An ideal photosensitizer is a substance with constant composition and a high degree of chemical 
purity, non-toxic in the dark and sufficiently stable under physiological conditions. It should be 
selectively accumulated into the malignant tissues and easily removed from the healthy tissues. It 
is commonly characterized by a high absorption coefficient in the phototherapeutic window 
(about 620-1000 nm) and as low as possible in the range 400-600 nm to avoid prolonged skin 
sensitivity towards solar irradiation after drug administration. The novel photoactive complexes, 
activated by the UV light are not suitable to be PDT drugs, since UV light is very high in energy, 
and can alone destroy the normal human skin cells. In addition, UV light does not penetrate 
human tissues as efficient as visible light. The photosensitizer must be photo stable and it should 
not be easily oxidized by singlet oxygen or other reactive oxygen species generated in situ. 
Acridine was the earliest known photosensitizer, reported to kill paramecia, followed by eosin 
for skin cancer treatment.[5,6] The U.S.FDA (Food and Drug Administration) has approved the 
photosensitizing agent called Porfimer sodium, or Photofrin, for use in the PDT to treat or relieve 
the symptoms of oesophageal cancer and non-small cell lung cancer.[7] The first- generation 
photosensitizers, chemically modified natural haematoporphyrins, have weak light absorption in 
the phototherapeutic window, a relatively poor specificity of uptake, and retention with respect 
to malignant and healthy tissues, as well as prolonged skin photosensitivity (usually 2-3 months), 
are their main drawbacks. 
The second-generation PDT sensitizers are mainly engineered, synthetic, and semisynthetic 
porphyrins.[8,9] They can be divided into five groups: organic dyes (eosin, rose Bengal, 
methylene blue), aromatic hydrocarbons (napthalenes, anthracenes, biphenyls, quinines), 
polypyrrolic and metallopolypyrrolic compounds, transition metal complexes and 
semiconductors. The third generation photosensitizers consist of the photosensitizing moiety 
linked to biomolecules such as monoclonal antibodies, peptide chains, proteins, which allow 
their selective delivery. This strategy overcomes difficulties in molecule recognition and specific 
binding to the tumour.   
The ideal metal complexes synthesized as PDT agents should be nontoxic in the dark, absorb in 
the phototherapeutic window (600-1000 nm), have good DNA binding ability, and able to photo 
destruct the cell. Ruthenium complexes are developed to ameliorate the cisplatin activity, 
particularly on resistant tumours, and to reduce the host toxicity at active doses. 
In photodynamic therapy the DNA photo nucleases / Photosensitizers are main key elements. 
Photofrin is the first approval drug for PDT treatment, after approval of this the researchers are 
started developing the more photo sensitizer’s drugs in treatment of PDT from all over the world. 
The ideal photosensitizer full fills the following the requirements: 
1. The photosensitizer must be able to produce the singlet oxygen efficiently, because the 
photochemical reaction of the singlet oxygen and norrish type II is responsible for the 
majority of the lesions generated during the photodynamic therapy. 
2. It must be stable and easily dissolve in the injectable solvents.  
3. After the administration of the compounds it must be show the high tumor accumulation 
and rapid action of clearance of tumor from the body. 
4. It should be chemically inert and pure.  
5. The compound should not shows the any dark toxicity, After the administration of the 
compounds it must be show the high tumor accumulation selectivity in the tumor tissue, 
to minimize the skin sensitivity. 
6. It must show the high absorption coefficient. 
7. If the photosensitizer is amphiphilic, it should be useful in crossing of cell membrane, 
because the chemical structure of the photosensitizer influences the distribution process 
in photodynamic therapy. 
 
In the presence specific wavelength of visible or nearer-infrared light, the DNA photo 
nucleases are excited. In PDT the photosensitizer molecule or the metabolic precursor is 
administrated to the patient and the tissue is exposed to suitable light. In the presence of 
light the photosensitizer is excited from the ground triplet state to an excited singlet state. 
Then it undergoes intersystem crossing to a longer-lived excited triplet state. The 
molecular oxygen chemical species at ground state are present in the tissue. When the 
photo sensitizer and an oxygen molecule are in proximity, an energy transfer can take 
place that allows the photo sensitizer to relax to its ground singlet state, and create an 
excited singlet state oxygen molecule. Singlet oxygen is a very destructive chemical 
species, it will very rapidly react with any nearby biomolecule, these destructive reactions 
will kill cells through apoptosis or necrosis. The generated reactive oxygen species 
(ROS) in PDT is damage the biomolecules like lipids, generating photoproducts. The 
mechanism involved in the generation of the ROS production is either type I or type II or 
both. In the type I mechanism the superoxide species are generated by the electron 
transfer from photo sensitizer, in the excited triplet state (T1), to ground-state oxygen 
(3O2), in the type II mechanism singlet oxygen is generated by energy transfer from photo 
sensitizer T1 to 3O2(12,13). 
 
The type I radical mechanisms may work to a limited extent in the absence of oxygen 
based on the oxygen independent photosensitized cross-linking of DNA. However, this 
does not lead to cell photoinactivation11. The singlet oxygen is a very a destructive 
chemical species and it will very rapidly react with the any biomolecules. These 
destructive reactions of singlet oxygen will kill the cells through apoptosis or by necrosis.  
 
 
The oxygen dependency of Photodynamic Therapy is an essential factor. The most of the 
normal tissues contains around the 5% of oxygen, it is supplied by the circulation of 
blood. The triplet state photo sensitizer lifetime is around 10µs11,which is enough or the 
triplet state oxygen to form singlet oxygen, so it is dependent on the oxygen 
concentration. The skin cells are often inflamed, vascularized and contain the slightly 
higher temperature. The photosensitizers have good selectivity for skin cancer cells11. 
Photodynamic therapy has the ability to induce extensive apoptosis of a cancer cells. 
Photodynamic therapy, it causes acute inflammation, expression of heat-shock proteins, 
invasion and the infiltration of the tumor by leukocytes, and have potency to increase the 
presentation of tumor-derived antigens to T cells. The apoptosis symbols in the cell, 
which includes chromatin condensation of chromatin, cell fragmentation, inter-
nucleosomal DNA cleavage and formation of apoptotic bodies. These formed bodies are 
removed by scavenging machrophages14. The ffragmentation of DNA in particular has 
been used as an indication of apoptosis. There are several assays are used to assess the 
extent of DNA fragmentation in cell, example, Agarose gel electrophoresis15 which is 
used to demonstrate  the DNA ladder pattern of which is generated by endonucleolytic 
cleavage of genomic DNA into nucleosomal size DNA of approximately 180 bases long 
(monomers) or oligonucleotides, which are multiples of 180 bases (oligomers)16.  
There are various metal compounds have been tested as possible photosensitizers for 
photodynamic therapy17.  
A. Transition metal complexes:  These metal complexes are can act as prospective 
photosensitizers through both energy and electron transfer to oxygen molecules. The 
photo generation of singlet oxygen studies involves polypyrrolic dyes and their 
metallo derivatives, but there is a significant number of other metal complexes are 
capable of photosensitized singlet oxygen generation. The mono and dinuclear RuII, 
CrIII, OsII, IrIII and PdII complexes with poly pyridines are used as singlet oxygen 
photo generators. 
B. The macro cyclic photosensitizers are modified by metal ions. Insertion of a metal 
ions to a polypyrrolic photo sensitizer, it can be modify the not only the properties of 
its ground and excited state photo physical and spectroscopic properties of the photo 
sensitizer but also its hydrophobicity, degree of aggregation, stability and 
consequently the route of the photosensitizer transport into the cell and its further 
distribution. 
C. Semiconductors: Redox properties of the excited semiconductor particles, particularly 
TiO2 are responsible for high efficiency of reactive oxygen species generation. TiO2 
itself shows a very weak or no toxicity in vitro and in vivo. A significant cytotoxicity 
of the TiO2 particles irradiated with UV light has been reported in the context of PDT 
applications. 
The extreme growth in the research and development of DNA photo nucleases based on 
Ruthenium complexes has been over the last decade. Various strategies have been used to 
improve the sequence selectivity of cleavage, which can arise from the preferential binding or 
activity at a certain site. There are several mechanisms can be engaged in photo activated DNA 
cleavage by ruthenium complexes:17-19 
A. Singlet oxygen formed by oxidation of the base via energy transfer from the triplet 
excited state of the photo cleaver. 
B. By direct electron transfer from the base to the excited state of the photo cleaver. 
C. Oxidation of the base by RuIII complex formed in situ by oxidative quenching of the 
triplet excited state of the corresponding complex. 
There are the three properties that can make ruthenium compounds well suited to target 
the cancer cells: 
I. Rate of ligand exchange 
II. The range of accessible oxidation states  
III. The ability of ruthenium to mimic ion in certain biological molecules. 
Many of the complexes have been evaluated for the clinical applications, particularly in the 
treatment of cancer, due in part to Ru(II) and Ru(I1I) complexes having the similar ligand 
exchange kinetics to those of Pt(II) complexes. Ligand exchange is an important determinant of 
biological activity, as very few metal drugs reach the biological target without being modified. 
Most undergoes interaction with macromolecules, such as proteins, or small S-donor compounds 
and /or water. Some of the interactions are essential for inducing the desires therapeutic 
properties of complexes. The rate of ligand exchange is dependent on the concentration of the 
exchanging ligand in the surrounding solution; diseases that alter these concentration in the cell 
or in the surrounding tissues can have an effect on the activity of the drug. 
Ruthenium is unique amongst the platinum group in that the oxidation states Ru(Il), Ru(III) 
and Ru (IV) are all accessible under physiological conditions. In these oxidation states the 
ruthenium centre is predominantly hexacoordiante with essentially octahedral geometry, and Ru 
(III) complexes tend to be more biologically inert than related Ru(II) and (IV) complexes. The 
redox potential of a complex can be modified by varying the ligands. In biological systems 
glutathione, ascorbate and single electron transfer proteins are able to reduce Ru(III) and Ru(IV), 
while molecular oxygen and cytochrome oxidase readily oxidize Ru(II). The redox potential of 
ruthenium compounds can be exploited to improve the effectiveness of drugs in the clinic. 
Cancer cells are known to have higher levels of glutathione and a lower pH than healthy tissues, 
creating a strongly reducing environment. If the active Ru(II) complex leaves the low oxygen 
environment, it may be converted back to Ru(III) by a variety of biological oxidants. Proteins 
that can catalyse the reduction of Ru(III) to Ru(II) include mitochondrial and microsomal single 
electron transfer proteins. The mitochondrial proteins are of particular interest in drug design as 
apoptosis, the desired mechanism for cell death, can be initiated in the mitochondria, as well as 
by other pathways, for instance, by the Fas/FasL pathway. Trans membrane electron transport 
systems can also reduce Ru(III) complexes outside of the cell and this is highly relevant to the 
mechanism of action of a ruthenium based drug in clinical use which has anticancer activity 
independent of cell entry. 
 
 
The low toxicity of ruthenium drugs is also believed to be due to the ability of ruthenium to 
mimic iron in binding to many biomolecules, including serum transferrin and albumin. These 
Two proteins are used by mammals to solubilise and transport iron, thereby reducing its toxicity. 
Since rapidly dividing cells, for example microbial infected cells or cancer cells, have a greater 
requirement for iron, they increase the number of transferrin receptors located on their cell 
surfaces, thereby sequestering more of the circulating metal loaded transferrin. As a result, 
ruthenium drugs bind more selectively to the cancer cells and hence are less toxic to the 
surrounding normal cells.18 
Ruthenium compounds have been selected as photosensitizers because of their unique 
combination of chemical stability, redox properties, excited state reactivity, luminescence 
emission and excited state lifetime. Ru2+ is a d6 system and the poly pyridine ligands are usually 
colorless molecules possessing the σ donor orbitals localized on the nitrogen atoms and π donor 
and π* acceptor orbitals more or less delocalized on aromatic rings. This opens up a range of new 
transitions, aside from the HOMO-LUMO transition observed in organic chromophores. This 
transition in inorganic photochemistry is called a ligand-field or ligand-ligand transition, as the 
excited state electron is located on the ligand.  Apart from this, because of the presence of the 
metal’s molecular orbitals, 3 other transitions are available:19,20 
a)  d-d transition, where an electron is excited from a metal orbital to an unoccupied metal 
orbital. This is usually referred to as a metal cantered (MC) transition  
b)  Transitions between the metal and the ligand. These can be either an electron excited 
from the ligand to the metal, called Ligand to Metal Charge Transfer (LMCT) or from the 
metal to the ligand (MLCT).  
c) Ligand – ligand transitions 
 
 Because of the energy differences between the various types of transitions, ligand field 
transitions are usually in the near-UV region, charge transfer transitions are in the visible region. 
The resulting emission from charge-transfer states is often highly colored. 
 
Ruthenium in oxidation state II is d6, and so as an octahedral complex its electrons are in the 
low-spin t2g6 configuration. Incident light at about 450 nm promotes one of these electrons to a 
ligand anti-bonding orbital, a metal to ligand charge transfer. Therefore, the S0 – S1 notation used 
in the Jablonski diagrams for excited state of Ruthenium compounds can be represented as 
1MLCT. Transfer to 3MLCT is efficient and so ruthenium complex’s photochemistry generally 
happens from here. From the Jablosnki diagram21, we can note that promotion of an electron 
from πM metal orbital to πL* ligand orbitals gives rise to metal to ligand charge transfer (MLCT) 
excited states whereas promotion of an electron from πM to σM* orbitals gives rise to metal 
centered (MC) excited states. Ligand centered (LC) excited states can be obtained by promoting 
an electron from πL to πL*. 
DNA – Deoxyribo nucleic acid. It is a molecule of great biological significance. The total DNA 
content of cell is called as Genome. It is unique to an organism and it is information bank for 
main all life process of the organism. The stretches of DNA called “genes” have the more 
important function of coding for protein synthesis. In the body DNA present as a double helix, in 
which each stand of DNA composed of a combination of four nucleotides, these are Adenine 
(A), Thymine (T), Guanine (G) and Cytosine (C)22. The structure of DNA does not only exist as 
secondary structures such as double helices, but it can fold up on itself to form tertiary structures 
by supercoiling. Supercoiling structure allows the compact packing of circular DNA. But 
Circular DNA still exists as a double helix, but is considered a closed molecule because it is 
connected in a circular form. The super helix structure is formed when the double helix is further 
coiled around an axis and crosses itself. Supercoiling is not only allows for a compact form of 
DNA, but the extent of coiling also affects the DNA interactions with other molecules by 
determining the ability of the double helix to unwind. The benefit of a supercoiled DNA 
molecule is its compatibility. A nick is a discontinuity in a double stranded DNA molecule where 
there is no phosphodiester bond between the adjacent nucleotides of one strand typically through 
damage or enzyme action. Supercoil is more compact, when Compare to the relaxed DNA 
molecule the supercoiled DNA contains the same length. This is reflected in experimentation as 
the supercoiled DNA moves faster than relaxed DNA. Therefore, the structural differences can 
be analyzed in the techniques such as gel electrophoresis and centrifugation. When DNA 
receives a signal that time only it starts the transcribing or replication, which is often in the form 
of a regulatory protein binding to a particular region of the DNA. Thus, if the binding specificity 
and strength of this regulatory protein can be mimicked by a small molecule, then DNA function 
can be artificially modulated, inhibited or activated by binding this molecule instead of the 
protein. Thus, this synthetic/natural small molecule can act as a drug when activation or 
inhibition of DNA function is required to cure or control a disease. DNA inhibition would 
restrict protein synthesis, or replication, and could induce cell death. Though both these actions 
are possible, mostly DNA is targeted in an inhibitory mode, to destroy cells for antitumor and 
antibiotic action.  
Drugs bind with the DNA by formation of both covalent and non-covalent bonding. Covalent 
binding of the DNA is irreversible and invariably leads to complete inhibition of DNA processes 
and subsequent cell death. The non-covalent bounded drugs are come under two classes: 
1. Minor groove binders:  Minor groove binding drugs are usually crescent shaped, which 
complements the shape of the groove and facilitates binding by promoting Van der Waals 
interactions. Additionally, these drugs can form hydrogen bonds to bases, typically to N of 
adenine and O of thymine. Most minor groove binding drugs bind to A/T rich sequences.  
2. Intercalates: These contain planar heterocyclic groups which stack between adjacent DNA 
base pairs. The complex, among other factors, is thought to be stabilized by π-π stacking 
interactions between the drug and DNA bases. Intercalates introduce strong structural 
perturbations in DNA. 
It is a method used to recognise the damage caused by the compound to the DNA. By applying 
the electrical filed to the Nucleic acid molecules they are separated and moves the negatively 
charged molecules through an Agarose matrix. The shorter molecules are moves faster and 
migrate more easily through the pores of the gel when compare to the longer molecules. This 
phenomenon is called sieving23. The most important factor is the length of the DNA molecule, 
smaller molecules travel faster. In this case, the supercoiled DNA moves faster than the nicked 
DNA due to its compact size and hence moves faster and to a longer distance. Increasing the 
Agarose concentration of a gel reduces the migration speed and enables separation of smaller 
DNA molecules. When applying the higher the voltage, the faster the DNA moves. But voltage 
is limited by the fact that it heats and ultimately causes the gel to melt and high voltages also 
decrease the resolution. The most commonly Ethidium bromide dye used to make DNA or RNA 
bands visible for Agarose gel electrophoresis. It fluoresces under UV light when intercalated into 
DNA (or RNA). By running DNA through an Ethidium bromide - treated gel and visualizing it 
with UV light, any band containing more than ~20 ng DNA becomes distinctly visible.   
 
  
Experimental Method 
The Ruthenium complexes under the study should be nontoxic in the dark, they absorb the 
phototherapeutic window (600-1000 nm), and these ruthenium complexes have good DNA 
binding ability and have ability to cause photo-destruction of the cell. Ruthenium complexes are 
developed to imitate the action of Cisplatin and shows better activity, mostly on the secondary 
tumors and to reduce the host toxicity at active doses. In this research project we have tested the 
possibility of 10 ruthenium complexes showing the good photodynamic activity.  
The 10 compounds tested are:  
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                                                  Where:  bpy: 2, 2’- bipyridine 
                                                                tpy: 2,2’,6,2’’- terpyridine 
                                                                Otf: trifluoromethylsulfonate 
                                                                Br-pic: 6- bromopicolinate 
                                                                mal: malonate 
                                                                tpa-: tris(pyridylmethyl)amine 
                                                               dmp: 2,9-dimethyl-1,10-phenanthroline 
                                                               pic: picolinate 
                                                               tmen: tetramenthylethylenediamine 
                                                               Me-pic: 6-Methylpicolinate 
These 10 compounds were tested for photo physical, photochemical and photo biological and 
photochemical activity in order to understand their photo anti-cancer activity. 
I. SPECTROSCOPIC STUDIES: 
All the 10 Ruthenium compounds under the study are colored. It is indicates that they absorb 
the visible region. The UV-Visible studies of all 10 compounds were performed by using the 
DMSO as solvent and by using the Ocean optics spectrophotometer. The obtained results of 
wavelength maxima and the molar extinction coefficient values were noted.  
II. FLUORESCENCE STUDIES:  
We performed the fluorescence studies of each ruthenium compound by using the Ocean 
optics instrument USB 2000 and  based the results we confirmed that these compounds did 
not shows the fluorescence.   
A. DNA BINDING STUDIES: 
DNA binding constant (kb), it is a measure of the binding ability of compound with the DNA. 
Binding constant, kb is measured by the optical rotation method as the both the complexes 
tested are showing an increasing hypochromicity as calf thymus DNA is added24. The DNA 
binding constant, Kb is measured by absorption changes during the DNA titration using the 
equation:  
([a-[b)/([b-[f) = (1/ Kb) x ( 1/[DNA]) + 1 
       [a = Molar extinction coefficients for the absorption values at a given DNA concentration. 
[b = Molar extinction coefficient for the absorption value of the complex fully bound to DNA. 
[f  = Molar extinction coefficient for the absorption value of the complex free in solution 
The absorption and [b of the bound complexes was determined from the titration where 
further addition of DNA did not result in changes to the spectrum.  The binding constant for 
each molecule was determined by plotting ([a-[b)/([b-[f) vs 1/[DNA], and Kb can be calculated 
as the reciprocal value of the slope.  
B. DNA PHOTOCLEAVAGE STUDIES: 
The gel electrophoresis is a technique which is used to separate the DNA fragments based on 
their size. In gel electrophoresis technique, first the gel is prepared. Gels are made of with 
agarose. It is a sea weed extract similar to the gelatin. The prepared gel gas a consistent 
appearance. This consistency offers resistance to the pieces of DNA as they try to move 
through the gel. Once the DNA samples are loaded onto the gel, an electric current is applied 
to the gel. The gel electrophoresis is based on the fact that the supercoiled DNA (uncut 
plasmid) will travel more rapidly than nicked DNA because of compact structure of 
supercoiled DNA.  The DNA is negatively charged due to the phosphate back bone. So DNA 
will move towards the positive electrode. 
In gel electrophoresis technique we prepared 1.5% Agarose gel. The 1.5% Agarose gel was 
prepared by dissolving 0.75 g of Agarose in 50 ml of 2.5 X Tris-EDTA buffer, with the 
application of heat using a hot plate and a magnetic stirrer until the morbid solution became 
clear. Ethidium bromide is used as a DNA staining agent. Ethidium bromide is mutagenic 
and should be handled with extreme care. The DNA is visualised in the gel by the addition of 
Ethidium bromide, which strongly binds to the DNA by intercalating between the bases 
.Buffers not only prevent ionic changes in the surroundings, but also provide ions to support 
conductivity.   Slowly, the gel solution was poured into the gel plate without forming the  any 
air bubbles. Pouring the gel solution slowly into the gel plate reduces the air bubbles in the 
gel. Insert the gel comb at one end. It can be left to solidify for 15-20 minutes. After the 
solidification of gel, the gel plate is then placed in the gel box, containing the buffer, and is 
connected to the power supply. Slowly remove the comb, care must be take while removing 
the comb. So that the wells formed are well resolved.  
The samples are prepared by adding the 5µl of DNA plasmid, 5µl of the complex and 2µl of 
the loading dye (Bromophenol blue) in a PCR tubes.  Loading dye (Bromophenol blue) 
provides the density required for the sample to be easily loaded in to the well. Loading dyes 
are negatively charged in the neutral buffers and thus move in the same direction as the 
DNA, allowing us to monitor the progress of the gel. Bromophenol blue migrates at a rate 
equivalent to 200-400 base pair DNA. So, to look at fragments near this size (ie. anything 
smaller than 600 bp), a different dye has to be used. Samples are then loaded in to the wells. 
The lid of the gel box is closed and voltage is applied. Stop the current supply when the 
loading dye has run ¾ the length of the gel. Carry the gel to a dark room to  
Look under the UV light, which is carcinogenic. So, protective glasses, gloves and long 
sleeves should be used to avoid the contact of UV light with the skin.  
C. SINGLET OXYGEN STUDIES11: 
Singlet oxygen is the only electronically excited state of molecular oxygen. Used 
intentionally as a deleterious species in photodynamic therapy, its role as a biological 
messenger is being increasingly recognized.1O2 is mainly a product of photochemical 
reactions and its synthesis is eukaryotes is very limited confined to specific type of cells like 
eosinophil’s and macrophages. It exists in excited state for only a short time before losing its 
reactivity by transferring excess energy to other molecules or by returning to ground state. 
There are no anti-oxidant enzymes for elimination of singlet oxygen and chemical scavengers 
that intercept this oxygen metabolite must be present at high concentrations to be effective.  
The lifetime of 1O2 in water, which is only up to 4µs, limits the distance it can diffuse in cells 
and therefore, restricts its reactivity to the so-called “spatially resolved” reactions29. It readily 
reacts with DNA, lipids and proteins. Among amino acids residues, the most reactive with 
singlet oxygen are histidine, tryptophan, methionine, cysteine and tyrosine which form short 
lived endo- or hydroxy peroxides. In the presence of redox-reactive metal ions, these 
peroxides undergo decomposition with the formation of reactive radicals that can propagate 
chain reactions and oxidative damage to other biomolecules30,31. In the presence of Fe2+ or 
Cu2+, lipid peroxides can participate in Fenton reactions to produce oxy- (LO) and peroxy- 
(LOO) radicals capable of inducing DNA damage.  
Methods for 1O2 detection include EPR spectroscopy using spin traps32, phosphorescence at 
1270 nm33 and chemical trapping34. The current spread of fluorescence imaging techniques 
has led to the development of a number of 1O2 fluorescent probes, such as trans-1-(2 -
methoxyvinyl) pyrene (MVP)35, dansyl – 2,2,5,5 – tetramethyl – 2,5 – dihydro – 1  H –
pyrrole (DanePy)36,or fluorescein-based probes such as DMAX or DPAX37. Invitrogen/ 
Molecular Probes has recently marketed a highly selective sensor for 1O2 without any 
appreciable response to hydroxyl radicals or superoxide, under the trade name Singlet 
Oxygen Sensor Green (SOSG) reagent®38. While the exact structure of SOSG has not been 
disclosed, its absorption spectrum resembles that of DMAX and it may therefore be assumed 
to contain a fluorescein bound to a dimethylanthracene derivative. 
The Singlet Oxygen Sensor Green reagent38 is highly selective for 1O2. Unlike other available 
fluorescent and chemiluminescent singlet oxygen detection reagents, it does not show any 
appreciable response to hydroxyl radical (.OH) or superoxide (.O2). This new singlet oxygen 
indicator initially exhibits weak blue fluorescence, with excitation peaks at 372 and 393 nm 
and emission peaks at 395 and 416 nm. In the presence of singlet oxygen, it emits a green 
fluorescence similar to that of fluorescein (excitation/emission maxima ~504/525 nm). The 
Singlet Oxygen Sensor Green reagent is supplied as a cell impairment derivative. 
Coming to the method, 100 µg vials in 330 µL of methanol was used to make a stock 
solution of ~500 uM which produced green fluorescence at 525 nm. Then, compound 
solutions were irradiated for their time of irradiation respectively, then 40 uL of sensor green 
(10 uM) was added and immediately a fluorescent reading was taken. The fluorescent 
reading of only sensor green (no compound) and only compound without irradiation with 
sensor green were also taken to compare the results. 
D. CELL STUDIES: 
The human skin fibroblast cells obtained from the ATCC are cultured in 600 ml culture 
flasks. The media is prepared by using the DMEM (High glucose media) (500 mL) , add 50 
mL Bovine Serum Albumin , 5 mL of Amphoterican B (Fungizone) and 2.5 mL of 
Gentamycin. Defrost all the above before 1 hour. For the 1st time when received cells 
distribute according to need add media. Media is changed at regular intervals (24, 48, 72 
hours) until the cells are fully grown. Once the cells have fully grown, they are ready to 
replacing. First the media is drained off. Wash the cells with PBS at least thrice, till get rid of 
color (10:5:5 mL). Add Trypsin (0.25%) to the flasks, spread throughout the flask and keep it 
in incubator for 1-2 min. as trypsin can digest the cells if placed in contact with them for a 
long time.  Take it out and tapped it in all directions. Trypsin which suspends the cells struck 
to the walls of the flask. Check for any cell attachment in microscope, they all should be 
floating. Immediately add the media to flask for inactivation of the trypsin, on an average 
each flask should have 50 ml media. Once media is added make sure cells are well 
distributed. The cells are then transferred to 60 mm2 petri dishes and allowed to grow until 
the plates is full.  
The precautions have to be taken: 
A. Maintain sterile conditions. 
B. Do not touch tips of containers. 
C. Media should not touch top of flask. 
D. Lids of the flask should not be too tight. 
After the cells fully growth (80-100%) in the petri dishes, they are aseptically transferred in 
to 24 well plates. Two such plates are made for each compound tested – Dark and Light.  The 
different concentrations of drug solutions are made like 50µM, 100µM, 150µM, 200µM …so 
on. These prepared drug solutions are added to each plate. One plate is not exposed to any 
light and immediately placed in the incubator after wrapping with sterilized aluminum foil 
and which is labeled as Dark. Another plate is irradiated for a definite of time (like 1hour) for 
the drug to be photo activated and hence show the activity, this plate is labeled as Light. Both 
the Dark and light plates are incubated for 24 hours and then the cell growth is observed. The 
cell growth in the wells is qualified by BCA protein assay.  
E. BCA PROTEIN ASSAY25,26,27: 
 BCA protein assay, it is a detergent compatible formulation based on Bicinchoninic acid (BCA) 
for the colorimetric detection and quantification of the total protein. In alkaline medium this 
BCA method combines the well-known reduction of Cu+2 to Cu+1 by protein with the highly 
sensitive and selective colorimetric detection of the cuprous cation using a unique reagent 
containing the Bicinchoninic acid25. The chelation of two molecules of BCA with one cuprous 
ion, which produce the purple colored reaction complex product. This is a water soluble complex 
which exhibits a strong absorbance at 562 nm that is nearly linear with increasing protein 
concentrations over the broad working range (20-2000 µg/ml).The BCA method is not a true 
end-point method, i.e, the final color continues to develop. However, following incubation, the 
rate of continued color development is sufficiently slow to allow large numbers of samples to be 
assayed together. 
 
 The BCA28 color formation is due to the macromolecular structure of protein, the number of 
peptide bonds and the presence of particular amino acids (cysteine, tryptophan and tyrosine).  
The cells are incubated for 24 hours are, exposed to the drug compounds. Then the media is 
drained off and the cells are washed with PBS solution (twice). Add 100 of surfactant (tween 80) 
to each well and incubated for 15 to 30 minutes. The cells are destructed by the surfactant. If all 
the cells are not destructed by the surfactant then add soap solution (Na lauryl sulfate) and put on 
mechanical shaker and observe under the microscope. After completion of all cell lysis, then 
BCA (Bicinchoninic acid) assay reagent is added to each well and incubated for 30 minutes to 1 
hour and then the absorbance reading can be noted by using the plate reader at 562 nm. 
Results and Discussion 
I. SPECTROSCOPIC STUDIES: 
After conducting the UV-Visible studies we got the   Absorbance, Molar absorptivity co-efficient 
( ε ) values for 10 ruthenium compounds: 
 
COMPOUND 
 
λ max(nm) 
 
ε (M-1cm-1) 
 
Mol. Wt 
 
[Ru (bpy)
2 
(CH
3
CN)
2
] (PF
6
)
2
 
 
425 
 
8270 
 
785.42 
 
[Ru (tpy)(bpy)(DMSO)] (PF
6
)
2
 
 
419 
 
8080 
 
858.59 
 
[Ru (tpy)(tmen)(DMSO)] (PF
6
)
2
 
 
428 
 
8161 
 
818.61 
 
cis [Ru (tpy) (Me-pic) (DMSO)] OTf 
 
447 
 
5790 
 
697.66 
 
[Ru(bpy)
2
(DMSO)Cl]PF
6
 
 
415.9 
 
6970 
 
671.99 
 
[Ru(tpa)(DMSO)Cl]( ClO
4
) 
 
417.1 
 
18011 
 
690.61 
 
[Ru (tpy)(dmp)(DMSO)] (OTf)2 
 
427 
 
4150 
 
918.87 
 
Ru(tpy)(Br-pic)(dmso)(PF6) 
 
440 
 
3529 
 
758.44 
 
Ru(tpy)(mal)(dmso) 
 
502 
 
5134 
 
550.56 
 
Ru(tpy)(bpy)(CH3CN)(Otf)2 
 
455 
 
10420 
 
829.73 
 
From the above data, it can be elucidated that all the ruthenium compounds are absorb light in 
the visible region. Molar extinction coefficient is a measure of how strongly a chemical absorbs 
the particular wavelength of light and the molar absorptivity co-coefficient has considerably 
increased with increasing the number of organic ligands. The compounds  [Ru(tpa)(DMSO)Cl]( 
ClO
4
) and Ru(tpy)(bpy)(CH3CN)(Otf)2  shows the maximum molar absorptivity co-coefficient 
values. All the ruthenium complexes show the maximum absorbance at a wavelength between 
the 415 nm to 502 nm. The compounds have to be irradiated at that particular wavelength to 
observe their photodynamic activity. 
 
II. DNA BINDING STUDIES 
DNA binding constant (kb), it is a measure of the binding ability of compound with the DNA. 
The DNA binding constant, Kb is measured by absorption changes during the DNA titration. 
Binding constant, Kb was measured by the optical titration method as all the complexes tested 
were showing an increasing hypochromicity as calf thymus DNA is added24.  
1) Complex compound Ru(tpy)(Br-pic)(dmso)(PF6) was titrated with CT-DNA at  the 
concentration of  800 µM until the absorbance became steady,  which meant that 
saturation or fully bound DNA with the compound. From these values, a graph was 
plotted using ([a-[b)/([b-[f) on Y-axis and 1/[DNA] on X-axis. The slope obtained was the 
value of 1/Kb which was found to be 9.4 x 10-6 and hence the DNA binding constant for 
this compound is 1.06 x 105/ M. 
 
2) For the compound Ru(tpy)(mal)(dmso) solution in DMSO was titrated with calf thymus 
DNA of concentration 250 µM until the absorbance at the beginning  0.789 and it was   
steadily decreased and became steady at 0.715. From this data, a graph was plotted using 
(ɛ
a-
ɛb
)/
(ɛ
b-
ɛf
) 
 
1/[DNA] 
DNA BINDING STUDIES OF  
Ru(tpy)(Br-pic)(dmso)(PF6) 
([a-[b)/([b-[f) on Y-axis and 1/[DNA] on X-axis, and the slope was calculated to be 1.98 x 
10-6. Therefore, the drug DNA intrinsic binding constant (1/kb) was found to be 5.05 x 
105 /M. 
 
3) The compound Ru(tpy)(bpy)(CH3CN)(Otf)2 which was showed better DNA binding 
when titrated with 800 µM concentration of CT-DNA. A graph was plotted using ([a-
[b)/([b-[f) on Y-axis and 1/[DNA] on X-axis, and the slope value was calculated to be 0.8 
x 10-6 and hence the intrinsic binding constant was found to be 1.16 x 106 /M. 
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DNA BINDING STUDIES OF 
Ru(tpy)(bpy)(CH3CN)(Otf)2 
4. For a compound [Ru(bpy)2(DMSO)Cl]PF6  the graph was plotted using ([a-[b)/([b-[f) on Y-axis 
and 1/[DNA] on X-axis, and the slope value was calculated to be 0.3427x10-6 and  the intrinsic 
binding constant was found to be 2.91x106M-1.  
 
 
5. For a compound [Ru(tpa)(DMSO)Cl](Clo4),  the graph was plotted using ([a-[b)/([b-[f) on Y-
axis and 1/[DNA] on X-axis, and the slope value was calculated to be 0.3502x10 -6 and the 
binding constant is found to be 2.855x106M-1 
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The results of this experiment showed that all the  compounds bind very tightly to the DNA 
when compared to the standard ethidium bromide. 
III. SINGLET OXYGEN STUDIES: 
In the singlet oxygen studies we measured the formation of 1O2 by fluorescence detection by 
using the singlet oxygen sensor green (SOSG) as fluorescent probe. At 504 and 525 nm Singlet 
oxygen sensor green emits the green fluorescence with an excitation and emission maxima 
correspondingly. In this research study, we observed that the probe doesn’t have any 
fluorescence by itself even when irradiated. We already confirmed that all the compounds 
doesn’t exhibit any fluorescence. We are already measured that when the probe is added all the 
compounds did not produce any fluorescence without the irradiation. When the mixture was 
irradiated, the compounds  Ru(tpy)(Br-pic)(dmso)(PF6), Ru(tpy)(mal)(dmso), 
Ru(tpy)(bpy)(CH3CN)(Otf)2 gave the following results:  
A. Ru(tpy)(Br-pic)(dmso)(PF6) did not show any fluorescence even when irradiated. This 
proves that the compound might not be having photodynamic activity. If it has any 
activity, it might not be due to the production of singlet oxygen. 
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B. Ru(tpy)(mal)(dmso) showed an intensity of  938.99 at 525nm when irradiated together 
which was high compared to the readings probe (28.18) and their mixture (29.96). 
 
C. Ru(tpy)(bpy)(CH3CN)(Otf)2 on irradiation in the presence of SOSG produced a 
fluorescence intensity of 1213. 
 
The results above show that Ru(tpy)(mal)(dmso) and Ru(tpy)(bpy)(CH3CN)(Otf)2  can act as 
good 1O2 photosensitizers. 
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IV. DNA PHOTOCLEAVAGE STUDIES: 
All the results which indicate that Ruthenium complexes strongly bind to CT-DNA in the groove 
mode. These complexes when photo activated could damage the DNA. The Agarose gel 
electrophoresis using pBR 322 DNA was performed by using the different concentrations of the 
compounds in both dark and photo-activated forms. The DNA photo cleavage studies of the 10 
ruthenium compounds produced the following results: 
1.  Ru(tpy)(Br-pic)(dmso)(PF6): 
 
The Lanes 1& 2-  indicates Control dark & irradiated; Lane 3 & 4 - 300µM dark & irradiated; 
Lane 5 & 6-350µM dark & irradiated; Lane 7 & 8 – 400µM dark & irradiated.  
From the above results, we can see that distance travelled by the DNA is decreses when the drug 
concentration is increses. This is a proof  for the compound have a high DNA binding constant 
and there is no photocleavage was observed and this is proves that the singlet oxygen studies that 
this compound might not be showing any photodynamic activity. 
2. [Ru (bpy)2 (CH3CN)2] (PF6)2 
 
           1          2                3                4                 5               6              7              8 
 
Lane 1: control dark, lane 2: control light, Lane 3: Sample 250 µM dark, Lane 4: Sample 250 
µM light, Lane 5: Sample 500 µM dark, Lane 6: Sample 500 µM light, Lane 7: Sample 750 µM 
dark, Lane 8: Sample 750 µM light. 
According to these results there is no DNA photocleavage was observed in Lane 1 and Lane 2. 
(No complex), with increasing concentration of the Ru (II) complex (lanes 3–8), the amount of 
Form I (supercoiled) of pBR322 DNA diminish gradually, whereas Form II (nicked) increases. 
When the concentration of the compound was gradually increased, the supercoils were relaxed to 
generate a slower-moving open circular form or nicked DNA (form II).   
 
 
DNA MIGRATION of  [Ru (bpy)2 (CH3CN)2] (PF6)2 
1                 2                    3                      4                      5 
 
Lane 1: control dark, Lane 2: Sample 250 µM dark, Lane 3: Sample 500 µM dark, Lane 6: 
Sample 500 µM light, Lane 7: Sample 750 µM dark, Lane 8: Sample 750 µM light. 
3. [Ru (tpy)(dmp)(DMSO)] (OTf)2 
 
Lane 1: control dark, lane 2: control light, Lane 3: Sample 100 µM dark, Lane 4: Sample 100 
µM light, Lane 5: Sample 200 µM dark, Lane 6: Sample 200 µM light, Lane 7: Sample 400 µM 
dark, Lane 8: Sample 400 µM light. 
According to the above results there is no DNA photocleavage was observed in Lane 1 and Lane 
2. (No complex), with increasing concentration of the Ru (II) complex (lanes 3–8), the amount of 
Form I (supercoiled) of pBR322 DNA diminish gradually, whereas Form II (nicked) increases. 
The DNA migration is high in light irradiated complexes. When the concentration of the 
compound was gradually increased, the supercoils were relaxed to generate a slower-moving 
open circular form or nicked DNA (form II).   
4. [Ru (tpy)(bpy)(DMSO)] (PF6)2 
 
According to the above results there is no DNA photocleavage was observed. When the 
concentration of the compound was gradually increased, the supercoils were relaxed to generate 
a slower-moving open circular form or nicked DNA (form II).   
DNA MIGRATION of [Ru (tpy)(bpy)(DMSO)] (PF6)2 
1           2                 3                   4                   5 
 
Lane 1: control dark, Lane 2: Sample 250 µM dark, Lane 3: Sample 500 µM dark, Lane 6: 
Sample 500 µM light, Lane 7: Sample 750 µM dark, Lane 8: Sample 750 µM light. 
5. Ru(tpy)(mal)(dmso) 
 
1                  2                        3                    4                    5                    6                  7                   
 
 Lane 1& 2-  Control dark & irradiated; Lane 3 & 4- 250µM dark & irradiated; Lane 5 & 6- 
300µM dark & irradiated and Lane 7 & 8 – 350µM dark & irradiated. 
For the Ru(tpy)(mal)(dmso) compound  we irradiated for 1.5 hours at 502 nm. According to 
these results there is no DNA photocleavage was observed in Lane 1 and Lane 2. (No complex), 
with increasing concentration of the Ru (II) complex (lanes 3–8), the amount of Form I 
(supercoiled) of pBR322 DNA diminish gradually, whereas Form II (nicked) increases. 
From the above results, we can see that distance travelled by the DNA is decreses when the drug 
concentration is increses. This is a proof  for the compound have a high DNA binding constant 
and the DNA migration studies prove that the good intrinsic binding of the compound. 
6. [Ru (tpy)(tmen)(DMSO)] (PF6)2 
 
According to the above results there is no DNA photocleavage was observed. When the 
concentration of the compound was gradually increased, the supercoils were relaxed to generate 
a slower-moving open circular form or nicked DNA (form II).   
7. cis [Ru (tpy) (Me-pic) (DMSO)] OTf  
 
From left to Right; Lane 1: control dark,  lane 2: control light, Lane 3: Sample 250 µM dark, 
Lane 4: Sample 250 µM light, Lane 5: Sample 500 µM dark, Lane 6: Sample 500 µM light, Lane 
7: Sample 750 µM dark, Lane 8: Sample 750 µM light. 
When the concentration of the compound was gradually increased, the supercoils were relaxed to 
generate a slower-moving open circular form or nicked DNA (form II).   
DNA MIGRATION of  cis [Ru (tpy) (Me-pic) (DMSO)] OTf 
1         2                   3                    4                    5 
 
Lane 1: control dark, Lane 2: Sample 250 µM dark, Lane 3: Sample 500 µM dark, Lane 4: 
Sample 750 µM dark, Lane 5: Control Dark. 
 
8. [Ru(bpy)2(DMSO)Cl]PF6  
 
From left to Right; Lane 1: control dark,  lane 2: control light, Lane 3: Sample 100 µM dark, 
Lane 4: Sample 100 µM light, Lane 5: Sample 400 µM dark, Lane 6: Sample 400 µM light, Lane 
7: Sample 600 µM dark, Lane 8: Sample 600 µM light. 
We can see that distance travelled by the DNA is decreses when the drug concentration is 
increses. This is a proof  for the compound have a high DNA binding constant and the DNA 
migration studies prove that the good intrinsic binding of the compound. Concentration gradient 
gel electrophoresis image of [Ru(bpy)2(DMSO)Cl]PF6. It is evident that the DNA begins to 
linearize at 400 µM, in the presence of UV-Visible light. 
 
 9. [Ru(tpa)(DMSO)Cl](Clo4) 
 
From left to Right; Lane 1: control dark,  lane 2: control light, Lane 3: Sample 100 µM dark, 
Lane 4: Sample 100 µM light, Lane 5: Sample 200 µM dark, Lane 6: Sample 200 µM light, Lane 
7: Sample 600 µM dark, Lane 8: Sample 600 µM light. 
Photo cleavage could not be attained even at higher concentrations of drug molecule, in the 
presence of UV-Visible light. 
 
 
10. Ru(tpy)(bpy)(CH3CN)(Otf)2 
The compound Ru(tpy)(bpy)(CH3CN)(Otf)2  was irradiated for 1 hour at 455 nm, we got the 
following results: 
 When circular plasmid DNA was subjected to electrophoresis, relatively fast migration was 
observed for the supercoiled (form I) as in Lanes 1 and 2. But, when the concentration of the 
compound was gradually increased, the supercoils were relaxed to generate a slower-moving 
open circular form or nicked DNA (form II).  This shows that the compound has good 
intercalation with DNA. The difference in the distance travelled by the bands also proves the 
very high binding constant of this compound. 
 
 
V. CELL STUDIES AND BCA PROTEIN ASSAY:  
After the cell studies we performed the BCA protein assay to quantify the cell viability. 
According to the results obtained, we calculated LD 50 values for all compounds. The results of 
BCA protein assay, plotted as a graph to calculate the LD 50 are as follows: – 
 
1                2                     3               4                5                 6               7                    8 
1. Ru(tpy)(mal)(dmso) 
 
Based on the graph, the LD 50 value in the dark found to be 1307 µM and in the light 848 µM. 
These results indicates that this compound is a good photo sensitizer and shows the activity when 
irradiated with visible light, in this activity the main mechanism involved is that production of 
the singlet oxygen. Compared to the concentrations we used, the lethal concentration is very high 
almost 5 fold and hence can be considered to have a very good potential. Its effect on cancer 
cells has to be tested to confirm its clinical use. 
 
 
 
 
 2. [Ru (bpy)2 (CH3CN)2] (PF6)2 
 
 
For a compound [Ru (bpy)2 (CH3CN)2] (PF6)2 , the human skin fibroblasts  at 50 min 
irradiation and 1 hour incubation the LD 50 cytotoxicity value found to be 2351 µM. The 
photocytotoxicity value for human skin fibroblasts at  lirr = 400 - 700 nm, 60 min (5 J/cm2 ,  
found to be 2463 µM.. 
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3. Ru(bpy)2(DMSO)Cl]PF6 
 
 
 
The LD 50 value in the dark found to be 5000 µM and in the light 2380 µM. These values are 
indicates that the compound might have good DNA binding and photo cleavage activity. 
4.  [Ru (tpy)(bpy)(dmso)] (PF6)2 
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 For a compound [Ru (tpy)(bpy)(dmso)] (PF6)2, the human skin fibroblasts at 1 hour incubation the 
LD 50 cytotoxicity value in the dark found to be 1257µM. The photo cytotoxicity value for 
human fibroblasts at lirr = 400 - 700 nm, 60 min (5 J/cm2, found to be 3148 µM.. 
5.  [Ru(tpa)(DMSO)Cl](Clo4)  
 
The LD 50 cytotoxicity value found to be 781 µM and in the photo cytotoxicity 700 µM. These 
values are indicates that the compound might have good DNA binding and photo cleavage 
activity. 
 
 
 
 
 
 
y = -0.0044x + 0.924 
R² = 0.8898 
y = -0.0052x + 1.03 
R² = 0.9286 
0%
20%
40%
60%
80%
100%
120%
0 20 40 60 80 100 120
A
xi
s 
Ti
tl
e 
Axis Title 
LIGHT
DARK
Linear (LIGHT )
Linear (DARK)
Linear ()
6. Ru(tpy)(Br-pic)(dmso)(PF6) 
 
 
The LD 50 cytotoxicity value found to be 1244 µM and in the photo cytotoxicity 488 µM. 
7.  [Ru (tpy)(tmen)(dmso)] (PF6)2 
 
For a compound  [Ru (tpy)(tmen)(dmso)] (PF6)2 , the human skin fibroblasts at  1 hour incubation 
the LD 50 cytotoxicity value in the dark found to be 2015µM. The photo cytotoxicity value for 
human skin fibroblasts at lirr = 400 - 700 nm, 60 min (5 J/cm2 found to be 1938µM. 
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8. cis [Ru (tpy) (Me-pic) (dmso)] otf  
 
 
 
For a compound cis [Ru (tpy) (Me-pic) (dmso)] otf, the human skin fibroblasts at 1 hour incubation 
the LD 50 cytotoxicity value in the dark found to be 4385 µM. The photo cytotoxicity value for 
human skin fibroblasts at lirr = 400 - 700 nm, 60 min (5 J/cm2 found to be 1551 µM.. 
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9. Ru(tpy)(bpy)(CH3CN)(Otf)2 
 
 
Based on the results, this compound has a good DNA photo cleavage activity at low 
concentrations. The LD 50 value in the dark found to be 1244 µM and in the light 488 µM. 
These values are indicates that the compound might have good DNA binding and photo cleavage 
activity; it might still be toxic when used clinically. The result of its effect on cancer cells has yet 
to be tested. 
Conclusion: 
 Octahedral Ruthenium complexes are employed to improve the sequence selectivity of cleavage 
which can arise from preferential binding at a certain site. All the Ruthenium complexes showed 
absorbance maxima in the visible region (≈415nm), and have good DNA binding ability. Gel 
electrophoresis data indicate that [Ru(bpy)2(DMSO)Cl]PF6  may have the ability to cleave the 
DNA. Cell studies indicated that, [Ru(bpy)2(DMSO)Cl]PF6, has enhanced activity in the presence 
of light compared to the dark, at similar concentration. [Ru(tpa)(DMSO)Cl](Clo4), has DNA 
good binding ability it could not cleave the DNA. This may be owed to its failure to generate 
reactive oxygen species. Ru(tpy)(mal)(dmso) and Ru(tpy)(bpy)(CH3CN)(Otf)2 could be proven 
to be good  potential photosensitizers owing to the consistent results observed in DNA photo 
cleavage studies, Singlet oxygen studies and the Cell studies using Human skin Fibroblasts. 
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